Eli Lilly Experiences Major Surge in Sales Due to Weight Loss Medication Demand; Adjusts Profit Forecast Following Cancer Treatment Acquisition
Eli Lilly has reported significant increases in its revenue and profits for the first quarter, driven by high demand for its weight loss and diabetes medications. However, the company has revised its annual profit projections downward following expenses associated with a recent acquisition in cancer treatment.
For fiscal year 2025, Eli Lilly now anticipates adjusted earnings per share to range between $20.78 and $22.28. This is a decrease from an earlier forecast of $22.50 to $24. The change accounts for a financial charge of $1.57 billion linked to the acquisition of an oral cancer therapy from Scorpion Therapeutics.
Despite the modification in profit outlook, the company continues to project sales for 2025 to fall within the $58 billion to $61 billion range.
In terms of the first quarter of the year, Eli Lilly disclosed revenue figures amounting to $12.73 billion, marking a 45% increase from the same timeframe the previous year.
The company’s net income for the first quarter was reported at $2.76 billion, or $3.06 per share. This is a rise from $2.24 billion, or $2.48 per share, recorded in the same quarter last year.
After adjusting for unique items including intangible asset valuations and other factors, Eli Lilly registered a first-quarter earnings per share of $3.34.




Leave a Reply